

## **Standard 4.6: Compliance with Evidence Based Guidelines - 2017**

*Rajasree Roy, MD – SFH Oncology*

- **ASCO guidelines:** April 18, 2016, DOI: 0.1200/JCO.2016.67.0182
  - **Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) –Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers**
- Trastuzumab plus chemotherapy is recommended for all patients with HER2-positive, node-positive breast cancer and for patients with HER2-positive, node-negative breast cancer tumors ( $\geq 1$  cm).

### Methods:

- Retrospective chart review of all female breast cancer patients diagnosed from 1/1/2015 to 12/31/15 with Her2/neu positive breast cancer, either node positive or
  - tumor size  $\geq 1$  cm who are candidates for adjuvant therapy
- ▶ Total 16 patients identified. All patients had curative surgery at presentation or after neoadjuvant therapy.
- Node positive = 6 patients
  - Node negative but T  $\geq 1$  cm= 8 patients
  - Nodal status unknown = 2 patients ( 1 due to frail state, the other had axillary node dissection 20 years ago). Both patients felt to be clinically node negative.
  - ER status:
    - 13 patients + ve
    - 3 patients – ve (2 patients needed neoadjuvant Rx)

## Node positive group (6)

- ▶ 4 patients treated with **neoadjuvant** followed by adjuvant therapy with chemotherapy + Trastuzumab
- ▶ 1 patient recommended and received **adjuvant therapy** with Chemo + Trastuzumab
- ▶ 1 patient was recommended **adjuvant** therapy incorporating Trastuzumab but was treated elsewhere

## Node negative group (10)

- ▶ Treatment history known in 9 patients
  - 8 patients received adjuvant therapy with Chemo + Herceptin
  - 1 patient (Nx) did not receive because of frail status but received antiestrogen therapy
- ▶ Treatment history unknown in 1 patient (MSK)
- ▶ Most commonly used chemotherapy – TCH or TH

## Honorable mentions

- ▶ 2 patients did not fulfil our criteria, but...
  - 1 with DCIS with microinvasion, Nx. Herceptin based treatment was recommended.
  - 1 with T = 0.7 cm. Received Taxol Herceptin

**Recommendation:** Maintain current standard.